Flu vaccines and antivirals - handle with care!
This article was originally published in Scrip
The "risk-based approach" is gaining ground, and for good reason. As concerns continue over safety and quality issues, and pharmaceutical manufacturing and testing become increasingly globalised, regulatory authorities around the world are having to become more selective in how they address safety issues.
You may also be interested in...
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.